Developing Diagnostic and Therapeutic Strategies to Reduce Hispanic Cancer Disparities Using Genetic, Molecular and Physiological Signatures from Mexican origin Cancer Patients

利用墨西哥裔癌症患者的遗传、分子和生理特征制定诊断和治疗策略，以减少西班牙裔癌症差异

• 批准号: 10588300
• 负责人: JIANYING ZHANG
• 金额: $ 2.53万
• 依托单位: UNIVERSITY OF TEXAS EL PASO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-15 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10588300
• 关键词: Address; Administrative Supplement; Antineoplastic Agents; Area; Bioinformatics; Biological Assay; Biomedical Research; Cancer Patient; Cancer Relapse; Cause of Death; Characteristics; Clinical; Clinical Trials; Collaborations; Collection; Complex; County; Data; Diagnostic; Drug Targeting; Early Diagnosis; Ethnic Origin; Ethnic group; Evidence based practice; FDA approved; Future; Genetic; Genetic Fingerprintings; Health; Health Disparities Research; Healthcare; Hispanic; Hispanic Populations; Histologic; Hospitals; Incidence; Individual; International; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of prostate; Medical; Mexican; Modeling; Molecular; Molecular Abnormality; Molecular Genetics; Molecular Probes; National Cancer Institute; Organ; Patients; Pharmaceutical Preparations; Physiological; Population; Positioning Attribute; Procedures; Proteomics; Race; Regimen; Research; Research Personnel; Risk; Sampling; Source; Techniques; Testing; Texas; Therapeutic; Therapeutic Intervention; Time; Tissue Sample; Tissues; Universities; anticancer research; base; biobank; biomarker signature; cancer health disparity; cohort; design; diagnostic strategy; diagnostic tool; drug sensitivity; exome sequencing; health disparity; hispanic community; individualized medicine; innovation; insight; metabolomics; multiple omics; novel; personalized approach; personalized therapeutic; specific biomarkers; stem; targeted treatment; therapeutic development; therapeutic target; tool development; treatment strategy

ABSTRACT Hispanics are the largest and fastest growing US ethnic demographic, and it is projected that the Hispanic share of the US population will increase to nearly 30% by 2050. Hispanics suffer from marked cancer health-related disparities and cancer is the leading cause of death for Hispanics in the US. Despite these considerable cancer health-related issues, Hispanics are underrepresented in cancer research in two significant areas. First, there is little research focused on understanding the genetic, molecular, and physiological aberrations in Hispanic cancer tissue, which may be particularly important for explaining Hispanic cancer health disparities. Second, there is a lack of availability of cancer tissue from Hispanic patients, a profound barrier for developing targeted therapeutic interventions. The objectives of the present Research Plan will directly address each of these deficiencies by establishing the first comprehensive Mexican Origin Cancer Tissue Biorepository and by developing, for the first time, novel genetic, molecular, and cellular signatures from primarily Mexican origin cancer patients as platforms to inform diagnostic and therapeutic strategies. Our focus on the Mexican origin population stems from the fact that the El Paso TX USA/Juárez CH MX borderplex is one of the most dynamic international borders in the world, with a population of more than 2.5 million residents. In El Paso County, TX 82% of residents are Hispanic, 96% of whom are of Mexican origin. The proposed studies will test the novel HYPOTHESIS that the reduction and elimination of cancer health disparities in Mexican origin individuals is dependent on identifying, understanding, and therapeutically-targeting the unique molecular, genetic and physiological signatures of cancer from these patients. Specific Aim 1 is focused on establishing the first comprehensive Mexican Origin Cancer Tissue Biorepository at The University of Texas at El Paso (UTEP) through our established collaborations with area hospitals in El Paso and Ciudad Juarez CH MX. This will allow local investigators access to Hispanic cancer patient samples for investigative purposes. Specific Aim 2 will address the fact that Hispanics are underrepresented in cancer research and clinical trials. Clinical observations such as poor survival may be attributed to a lack of unknown genetic abnormalities. Therefore, we propose to perform the first FDA-approved drug assay with comprehensive multiplex proteomic analysis and Whole Exome Sequencing (WES) on patient samples obtained from the Mexican Origin Biorepository. Specific Aim 3 will develop the first diagnostic tools using molecular, multi-omics, and bioinformatic approaches to address the growing incidences of liver and prostate cancer within the Hispanic community. The current research findings will exert a sustained and powerful influence on the field by providing novel insight and direction for reducing the deleterious effects of cancer in Hispanics of Mexican origin, and will establish The UTEP BBRC and the El Paso/Juarez borderplex as critical drivers of Hispanic cancer health disparities research.

抽象的 西班牙裔是美国种族人群最大，增长最快的人，预计西班牙裔分享 到2050年，美国人口将增加到近30％。西班牙裔遭受了与癌症健康有关的明显 差异和癌症是美国西班牙裔人死亡的主要原因。尽管有这些癌症 与健康相关的问题，在两个重要领域的癌症研究中，西班牙裔人数不足。首先，那里 很少的研究重点是了解西班牙裔的遗传，分子和身体像差 癌组织，这对于解释西班牙裔癌症健康分布特别重要。第二，那里 是缺乏西班牙裔患者癌组织的可用性，这是发展目标的深刻障碍 治疗干预措施。本研究计划的目标将直接解决这些目标 通过建立第一个全面的墨西哥癌组织生物座席和通过 从原发性墨西哥起源的新型遗传，分子和细胞特征首次发展 癌症患者是为诊断和治疗策略提供信息的平台。我们专注于墨西哥起源 人口植物从El Paso TX USA/JuárezCH MX Borderplex是最动态的 世界上国际边界，人口超过250万。在德克萨斯州埃尔帕索县 82％的居民是西班牙裔，其中96％是墨西哥起源。拟议的研究将测试小说 假设减少和消除墨西哥起源个人的癌症健康分布是 取决于识别，理解和治疗靶向独特的分子，遗传和 这些患者的癌症的生理特征。特定目标1专注于建立第一个 德克萨斯大学El Paso大学（UTEP）的综合墨西哥癌症组织生物库 通过我们与El Paso和Ciudad Juarez CH MX的地区医院建立的合作。这将允许 当地研究人员出于调查目的获取西班牙癌症患者样本。具体目标2将 解决了西班牙裔在癌症研究和临床试验中的人数不足的事实。临床观察 诸如生存差的可能归因于缺乏未知的遗传异常。因此，我们建议 通过全面的多重蛋白质组学分析和整个外显子组，执行第一个FDA批准的药物测定 从墨西哥起源生物座席获得的患者样品上的测序（WES）。具体的目标3将 使用分子，多词和生物信息学方法来开发第一个诊断工具来解决该工具 西班牙裔社区内肝脏和前列腺癌的起初越来越多。当前的研究发现将 通过提供新颖的洞察力和方向来减少持续和强大的影响 癌症在墨西哥血统的有害影响，并将建立UTEP BBRC和EL Paso/Juarez Borderplex是西班牙癌症健康分布研究的关键驱动因素。